Claims for Patent: 11,596,600

Summary for Patent: 11,596,600

Title:	Vasoconstriction compositions and methods of use
Abstract:	The invention generally relates to compositions for inducing vasoconstriction. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.
Inventor(s):	Gerald Horn
Assignee:	Eye Therapies LLC
Application Number:	US17/585,395
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,596,600
Patent Claims:	1. A method for reducing eye redness in a human subject having ocular hyperemia, comprising topically administering to an eye of said human in need of said reduction of eye redness an ocular drop comprising about 0.025% weight by volume brimonidine as the sole active ingredient, wherein the ocular drop has a pH between 5.5 to 6.5. 2. The method of claim 1, wherein said human subject is in need of reduction of eye redness for the purpose of an improved cosmetic appearance of the eye to which the drop is administered. 3. The method of claim 1, wherein the ocular drop reduces redness in the eye to which the ocular drop was administered to improve the aesthetic appearance of said eye. 4. The method of claim 1, wherein the ocular drop induces a low incidence of rebound hyperemia in the eye of the human subject administered the ocular drop. 5. The method of claim 2, wherein the ocular drop induces a low incidence of rebound hyperemia in the eye of the human subject administered the ocular drop. 6. The method of claim 4, wherein the incidence of rebound hyperemia is less than about 6.6%. 7. The method of claim 1, wherein said human is in need of reduction of eye redness to improve the aesthetic appearance of the eye to which the ocular drop is administered. 8. The method of claim 7, wherein the eye redness of said human before administration of said ocular drop is excessive. 9. The method of claim 1, wherein the eye redness of said human resulted from ocular itch. 10. The method of claim 7, wherein the ocular drop induces a low incidence of rebound hyperemia in the eye of the human subject administered the ocular drop. 11. The method of claim 10, wherein the incidence of rebound hyperemia is less than about 6.6%. 12. The method of claim 1, wherein the eye redness of said human is not associated with an ocular disease or the result of a surgical procedure on the eye. 13. The method of claim 1, wherein the method retains normal intraocular pressure in the eye of the human subject administered the ocular drop. 14. The method of claim 1, wherein the method does not lower the intraocular pressure in the eye of the human subject administered the ocular drop. 15. The method of claim 12, wherein said human is in need of reduction of eye redness to improve the aesthetic appearance of the eye to which the ocular drop is administered. 16. The method of claim 12, wherein said human is in need of reduction of eye redness to improve the cosmetic appearance of the eye to which the ocular drop is administered. 17. The method of claim 12, wherein the ocular drop reduces redness in the eye to which the ocular drop was administered to improve the aesthetic appearance of said eye. 18. The method of claim 12, wherein the eye redness of said human resulted from ocular itch. 19. The method of claim 15, wherein the eye redness of said human is excessive before administration of said ocular drop. 20. The method of claim 15, wherein the eye redness of said human resulted from ocular itch. 21. The method of claim 19, wherein the ocular drop induces a low incidence of rebound hyperemia in the eye of the human subject administered the ocular drop. 22. The method of claim 20, wherein the ocular drop induces a low incidence of rebound hyperemia in the eye of the human subject administered the ocular drop. 23. The method of claim 16, wherein the ocular drop induces a low incidence of rebound hyperemia in the eye of the human subject administered the ocular drop. 24. The method of claim 17, wherein the ocular drop induces a low incidence of rebound hyperemia in the eye of the human subject administered the ocular drop. 25. The method of claim 20, wherein the ocular drop induces a low incidence of rebound hyperemia in the eye of the human subject administered the ocular drop. 26. The method claim 21, wherein the incidence of rebound hyperemia is less than about 6.6%. 27. The method claim 21, wherein the incidence of rebound hyperemia is less than about 6.6% and the method retains normal intraocular pressure in the eye of the human subject administered the ocular drop. 28. The method of claim 1, wherein the weight by volume brimonidine is 0.025%. 29. The method of claim 4, wherein the weight by volume brimonidine is 0.025%. 30. The method of claim 25, wherein the weight by volume brimonidine is 0.025%.